Share
PrintTest Details
Turnaround Time
1 - 5 days
Use
Differential diagnosis of acute or recent infection from past infection with human parvovirus associated with erythema infectiosum (fifth disease), aplastic crisis, and fetal infection
Test Includes
Human parvovirus B19, IgG; human parvovirus B19, IgM
Methodology
Enzyme immunoassay (EIA)
References
Anderson MJ, Hall SM, Serjeant GR. Current Trends: Risks Associated With Human Parvovirus B19 Infection.MMWR. 1989 Feb 17; 38(6):81-88,93-97.
Griffin TC, Squires JE, Timmons CF, Buchanan GR. Chronic human parvovirus B19-induced erythroid hypoplasia as the initial manifestation of human immunodeficiency virus infection. J Pediatr. 1991 Jun; 118(6):899-901. 1645771
Schwarz TF, Modrow S, Hottentrager B, et al. New oligopeptide immunoglobulin G test for human parvovirus B19 antibodies. J Clin Microbiol. 1991 Mar; 29(3):431-435. 1645365
Schwarz TF, Nerlich A, Hottenträger B, et al. Parvovirus B19 infection of the fetus. Am J Clin Pathol. 1990 Jul; 96(1):121-125. 1648876
Additional Information
IgM antibodies are detectable two weeks after exposure. IgG antibody production usually occurs 18 to 24 days after exposure. The presence of IgM antibodies to parvovirus B19 provide definite evidence of recent infection.
Specimen Requirements
Information on collection, storage, and volume
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Storage Instructions
Maintain specimen at room temperature.
Causes for Rejection
Hemolysis; lipemia; gross bacterial contamination